ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

ASCO 2026 data show perioperative enfortumab vedotin plus pembrolizumab boosts EFS, OS, and pCR in cisplatin-eligible MIBC.

ASCO 2026: Glofitamab monotherapy shows durable remissions in relapsed mantle cell lymphoma after BTKi, with manageable CRS.

At ASCO 2026, CHRYSALIS-2 data show amivantamab plus lazertinib extends survival in atypical EGFR-mutated NSCLC, reshaping first-line care.

This interview discusses emerging immunotherapy trends at the 2026 ASCO Annual Meeting, including cancer vaccines, cell-based therapies, ADCs, and AI-driven immune profiling tools poised to reshape oncology care.

Proteomic liquid biopsy technology may improve early breast cancer detection, guide targeted therapy selection, and support longitudinal treatment monitoring in oncology care.

Phase 3 UTOPIA trial shows UGN-103 intravesical mitomycin after TURBT achieves 78% complete response with favorable safety.

ASCO pooled phase 3 data show that pirtobrutinib in treatment‑naive CLL/SLL delivers 93% responses, durable control, and low cardiac risk.

Selinexor plus ruxolitinib significantly improved spleen volume reduction in JAK inhibitor–naive myelofibrosis, supporting its potential as a novel frontline combination strategy.

Nikita Dahake, MD; Hossein Borghaei, DO, MS; and Yasmine Baca, MS, PhD candidate, MB(ASCP)CM, explore how distinct HER2-alteration subtypes in non-small cell lung cancer (NSCLC) impact survival outcomes, co-mutation profiles, and treatment response to immunotherapy-based regimens.

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

The long-term outcomes from the CARTITUDE-1 trial in multiple myeloma and durable complete response data from the STARGLO trial in diffuse large B-cell lymphoma can be significant for these disease states.

Obecabtagene autoleucel shows promising efficacy and safety in treating relapsed/refractory B-ALL, benefiting patients of all ages, including older adults.

Ropeginterferon alfa-2b shows promising results in treating preprimary myelofibrosis, enhancing clinical responses and safety in patients.

Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.

Gayathri Namasivayam, PhD, discusses how large language models are being used to extract structured oncology data from unstructured electronic health records to improve clinical efficiency, support real-world evidence generation, and enhance oncology pharmacy workflows.

INCB057643 shows promise in treating myelofibrosis, enhancing anemia and symptom relief.

The agent continues to show promising clinical benefit despite being pulled from the market in 2023.

Combining benmelstobart and anlotinib shows promise for patients with squamous non-small cell lung cancer.

Jaume Capdevila, MD, PhD, discusses phase 1 data showing promising efficacy and manageable safety for obrixtamig in patients with high DLL3-expressing extrapulmonary neuroendocrine carcinomas, along with ongoing trials evaluating its use in both monotherapy and combination settings.

Janet Espirito, PharmD, discusses real-world outcomes from a large community oncology study showing that patients with BRAF-mutated melanoma—including those with brain metastases—experienced similar benefit from frontline immune checkpoint inhibitor (ICI) therapy.

The emergence of biomarkers plays a critical role in the growing success of treatment.

Ribociclib plus endocrine therapy shows improved survival in HR+, HER2- breast cancer, but its cost-effectiveness raises concerns in the US market.

Ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) improved invasive disease-free survival (iDFS) while allowing for better quality of life in hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) early breast cancer.

The data from the 5-year analysis of arm C validate and support the efficacy and safety of zanubrutinib for treatment-naive patients with CLL/SLL harboring del(17p).

Significant challenges persist, particularly in low- and middle-income countries.

Building on positive event-free survival (EFS) and overall survival (OS) rates in the original analysis of CheckMate 77T, new results indicate sustained survival over 3 years following treatment with nivolumab compared with placebo in non-small cell lung cancer (NSCLC).

Asciminib shows superior tolerability over nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, enhancing treatment options and patient outcomes.

Nivolumab plus relatlimab does not significantly improve recurrence-free survival in patients with stage 3, 4 melanoma.

Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option.

A new study reveals the combination therapy enhances safety and efficacy for high-risk BRAF-mutated stage II melanoma.